# Galapagos

> Galapagos is a VC fund backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Mechelen-bovelingen, Belgium
- Total investments: 5
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/biofocus/
- X (Twitter): https://twitter.com/GalapagosNV
- Website: http://www.glpg.com

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

## Contacts

5 contacts available for Galapagos. Shizune tracks 7 team members at Galapagos. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/galapagos?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $52M–$125M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Life Science | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 20% |
| Belgium | 1 | 20% |
| United States | 1 | 20% |
| The Netherlands | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andre Hoekema | Chief Business Officer | 0 | https://shizune.co/investors/profile/andre-hoekema |
| Kruti Popat | Director, Customer Insights & Engagement | 0 | https://shizune.co/investors/profile/kruti-popat |
| Michele Manto | Chief Commercial Officer | 0 | https://shizune.co/investors/profile/michele-manto |
| Paul Passier | Director Clinical Pharmacology | 0 | https://shizune.co/investors/profile/paul-passier |
| Paul Stoffels | Chief Executive Officer | 0 | https://shizune.co/investors/profile/paul-stoffels |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Third Arc Bio | Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M | Series A | Feb 04, 2026 |  |
| Terratis | Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach. | $1.6M | Seed | Mar 07, 2025 |  |
| Frontier Medicines | Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $80M | Series C | Feb 22, 2024 |  |
| Vitalnext | Vitalnext brings together the worlds of Life Sciences and consumer products. We develop products with evidence-based health benefits for the ageing population. Healthy Ageing is an important topic in most societies throughout the world. The increasing life expectancy of most people creates a demand for products that keeps us in good health forprolonged periods of time. These products are commercialized via distribution- or licensing agreements with specialized business partners. Vitalnext’s most advanced product is an innovative medical nutrition that aims to not only improve body weight in malnourished people, but also improves the body composition in these patients by a preferential increase in muscle mass. |  | Seed | Jul 01, 2013 |  |

5 of 5 investments shown.

## Co-investors
- [Aberdeen Investments](https://shizune.co/investors/profile/aberdeen-investments) — VC Fund, 1 deal together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 1 deal together
- [AxLR](https://shizune.co/investors/profile/axlr) — VC Fund, 1 deal together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in Belgium](https://shizune.co/investors/life-science-vc-funds-belgium)

## FAQ

### What does Galapagos invest in?

Galapagos invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Galapagos's check size?

Galapagos typically joins rounds of $52M–$125M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Galapagos participates in.

### How do I contact Galapagos?

Public channels for Galapagos include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Galapagos?

The team at Galapagos includes Andre Hoekema (Chief Business Officer), Kruti Popat (Director, Customer Insights & Engagement) and Michele Manto (Chief Commercial Officer), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co